Introduction
Mantle cell lymphoma (MCL) comprises approximately 6% of NHL.
1 It characteristically presents in middle aged to older adults with a median age of 60 years and a male predominance. Patients usually present with lymphadenopathy and advanced stage disease. Hepatosplenomegaly and involvement at other extranodal sites is common.
MCL is generally considered to be an incurable disease, with median survival of 3-5
years. 2 The hallmark genetic abnormality is the t(11;14)(q13;q32) leading to overexpression of cyclin D1. This leads to dysregulation of the cell cycle and, combined with chromosomal instability and activation of cell survival mechanisms, contributes to the pathogenesis of MCL. 3 Recently, it has been recognized that the clinical behavior of MCL is heterogeneous, and that some patients experience a particularly indolent course. Case reports of patients with lymphadenopathy and minimal involvement by MCL document prolonged survival even without therapy. 4, 5 Indeed, selected asymptomatic patients may be managed expectantly, without risk of worsening their long-term prognosis. 7 There is immunologic and genomic evidence that two distinct subgroups of mantle cell leukemia exist with differing clinical course (aggressive versus indolent clinical behavior). 8, 9 Subsequent studies have identified MCL patients with non-nodal disease and mutated IgH V genes who exhibit a good prognosis. 10 These patients often presented with blood involvement and varying lymphocyte count (ranging from normal to markedly elevated), variable CD5 expression, and splenomegaly. However, such cases remain incompletely characterized, especially with regard to bone marrow findings.
We report a retrospective analysis of indolent MCL patients presenting with lymphocytosis but lacking lymphadenopathy, splenomegaly, or evidence of gastrointestinal or splenic involvement. We note a curious propensity for kappa light chain usage (as opposed to the known lambda preference in typical MCL), demonstrate a low tumor burden, single-cell interstitial bone marrow pattern, and discuss the concept of a MCL-type of monoclonal B-cell lymphocytosis.
Design and Methods

Patients
The Cleveland Clinic Institutional Review Board (IRB) and the Cross Cancer Institute IRB granted approval for the study before its initiation. Cases of incidental leukemic mantle cell lymphoma discovered at Cleveland Clinic, Cleveland OH and Cross Cancer
Institute, Edmonton, Alberta between January 2000 and Dec 2010 were retrospectively identified by initially using a search for patients with CD5+ lymphoproliferative disorders characterized as mantle cell lymphoma at presentation. The diagnoses were established by peripheral blood morphology review, flow cytometry, and cytogenetic and/or FISH analysis confirming a t(11;14)(q13;q32) or IGH@/CCND1;. Patients with lymphadenopathy, gastrointestinal involvement or splenic involvement were excluded.
Routine endoscopic staging examination was not performed on all 8 patients, so we cannot exclude subclinical GI involvement in those patients. In order to estimate the prevalence of pure leukemic and non-nodal indolent MCL at Cleveland Clinic, a companion search was perfomed to identify additional cases of low stage disease that may have been initially excluded by specifically searching for non-nodal patients with t(11:14) lymphocytosis who may have additionally had gastrointestinal or splenic involvement (thus meeting criteria for non-nodal MCL as described by Orchard et al). 10 The results of this are described in the body of the manuscript. Bone marrow biopsies performed at the time of diagnosis were reviewed, if available. Chart review was performed for clinical characteristics, follow-up, and laboratory values.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues from available diagnostic bone marrow trephine biopsies on selected cases were characterized by immunohistochemistry using the following antibodies at the time of diagnosis: L26-CD20 (Dako, Carpinteria, CA, USA),
CA, USA), and SP4-cyclin D1 (Thermo Scientific, Waltham, MA, USA). Stains were performed on an automated stainer using heat induced epitope retrieval (CC1 standard, Ventana Benchmark) and 3,3'-Diaminobenzidine detection (DAB, Ventana). Double-labeling immunohistochemistry was performed using an antibody cocktail for L26-CD20 (Dako, Carpinteria, CA; 1:100 dilution) and rabbit polyclonal-SOX11 (Sigma, St. Louis, MO;
1:50 dilution) using DAB detection for CD20 and fast red for detection for SOX11
(Ventana). SOX11 protein expression was identified as strong nuclear staining in the lymphocytes as originally described 9 .
Flow cytometry
Flow cytometric immunophenotyping was performed as part of the diagnostic workup 
Karyotyping
Conventional chromosome analysis was perfomed using G-banded metaphases obtained from stimulated bone marrow cultures according to standard cytogenetic protocols in 3 bone marrow biopsies done at diagnosis and on one biopsy performed several years after therapy was initiated. The karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN). FISH analysis was performed on either cell suspensions from peripheral blood at the time of diagnosis or on paraffin-embedded tissue blocks using a dual color fusion FISH probe set for 11q13 (Vysis LSI CCND1) and 14q32 (Vysis LSI IGH) intended to detect the reciprocal translocation (Abbott, Abbott Park, IL, USA) using methods described. 11 The cut-off for 7 positive CCND1/IGH FISH was the presence of fusion signal in 10% of cells, based on laboratory established thresholds.
Results
Clinical Features
Six patients from Cleveland Clinic had isolated leukemic MCL (+/-bone marrow involvement) without overt tissue involvement (nodal, splenic, or gastrointestinal).
Search results from Cross Cancer Institute yielded an additional 2 cases who met these criteria. Thus a total of 8 patients (5 males, 3 females) with a median age of 60.5 years (range 48-77 years) were discovered to have mild to moderate absolute lymphocytosis with features of mantle cell leukemia and formed the basis of this study.
The white blood cell counts were normal to mildly elevated (median=14.2x10 The basic clinical and laboratory features are shown in Table 1 .
Pathologic Features
The morphology of circulating lymphoma cells was classified according to the FrenchAmerican-British criteria 12 .
The peripheral blood smears demonstrated the presence of atypical small-to-medium-size lymphocytes with high nuclear:cytoplasmic ratios, slight nuclear clefts or irregularities and hyperchromatic condensed chromatin in the majority of cases (classic type). Two cases showed small-cell (CLL-like) morphology. One patient had prolymphocytic cells ( Figure 1D ).
Bone marrow biopsy was performed at diagnosis in 6 of the 8 cases. Routine hematoxylin and eosin stained sections of the trephine biopsy showed a normocellular bone marrow with trilineage hematopoiesis in all cases. Biopsies were also evaluated by immunohistochemistry for CD3, CD20, CD5, and cyclinD1. The five cases with no obvious infiltrates on H&E sections showed interstitial involvement by scattered lymphocytes, singly or in small clusters, with a similar pattern of CD20 and cyclinD1
immunostaining, estimated at 1-5% of bone marrow cellularity (Figure 2 ).
The remaining case had a pattern of involvement in the form of small interstitial aggregates of CD20+/cyclinD1+ lymphocytes which occupied 10% or less of total cellularity CD22 was expressed in all 3 patients for which it was examined. CD38 was negative (<20%) in the 3 patients with available data. CD23 expression was examined in all 8
patients and showed at least a subset of positive cells (>20% of cells) in 5 cases (63%).
Strikingly, 7 of 8 cases demonstrated kappa monotypic surface immunoglobulin light chain with the remaining case lacking detectable surface light chain expression (Table 2) .
Clinical Follow-up (Table 3) The median follow-up for all patients was 27 months, and of the 7 survivors was 26 months (range 5-89 months). All survivors are alive with no evidence of overt disease (i.e. currently lacking lymphadenopathy or splenomegaly) and with stable lymphocytosis. In our follow-up, we estimated lymphocyte doubling time as number of months from the first discovered lymphocytosis to the first documented doubling of the absolute lymphocyte count. Five patients doubled their counts over a median of 18 months (range 6-24 months). The remaining 3 patients have been followed for 5, 26 and 89 months without a doubling of their count.
Two patients required treatment. Treatment was initiated for patient 3 at 26 months due to rising peripheral lymphocyte counts. Multiple chemotherapeutic regimens, including rituximab, were used over the course of approximately 6 years with longest observed remission of 5 years. However, the patient ultimately died of disease at 109 months.
Single agent rituximab (8 cycles) was initiated for patient 2 at 30 months due to rising lymphocyte counts as well as fatigue and night sweats. This patient responded to therapy, was alive and well at 89 months, with minimal absolute lymphocytosis, absent symptomatology and no adenopathy or splenomegaly. Of note, this patient was characterized as having prolymphocyte-like MCL morphology. 
Estimated
Discussion
MCL is considered a lymphoma with moderately aggressive behavior and median survival of only 3-5 years.
2 Peripheral blood involvement of MCL is variable but common, depends on initial staging techniques applied, and is reported in 13-92% of patients with newly diagnosed nodal disease. [15] [16] [17] [18] Early reports found leukemic involvement to signify aggressive disease with poor prognosis [13] [14] [15] [16] [17] [18] [19] ; however, a growing literature has identified an indolent form of mantle cell lymphoma with relatively long survival even without therapy 4-5, 7,9-10 . Features that may identify these patients include non-nodal disease or a lack of clinical symptoms. 6,10 Detailed pathologic features and bone marrow findings in these indolent MCL patients are lacking. We report our experience with eight patients with isolated lymphocytosis due to MCL cells and describe the immunophenotype and pattern of bone marrow involvement.
In our series, the median age and slight male predominance of these patients with isolated lymphocytosis is similar to that seen in MCL in general. 15 All patients except one were alive without clinical evidence of disease progression at 26 months (median follow-up of surviving patients). All examined patients had subtle, low level bone marrow involvement. Thus, these patients are a cohort of indolent MCL presenting with incidentally discovered systemic low tumor burden disease. In recent years, it has been recognized that despite the generally observed poor prognosis of MCL, a subset of patients may follow an indolent course with long survival. Our cohort resembles a prior series of non-nodal MCL cases 10 . In that study, the M:F was 2.0 with a mean age of 65 years. However, in contrast to our patients, the majority of those patients (75%) had splenomegaly and/or gastrointestinal involvement at presentation. Such patients were excluded from our series. A feature noted by the investigators was somatic hypermutation of the immunoglobulin (Ig) VH genes, reported in CLL to portend a favorable prognosis 21 . We did not have sufficient sample to perform this analysis.
Another series of indolent non-nodal, leukemic MCL has also been reported, characterized by hypermutated Ig VH genes and a non-complex karyotype 9 . Again, splenomegaly or gastrointestinal involvement were common.
In an effort to characterize this specific and unique subset of leukemic MCL, we searched for additional cases at Cleveland Clinic that might have been excluded due to splenomegaly or gastrointestinal involvement. Additional cases were identified by searching for all non-nodal cases as a surrogate for indolent disease as done by Orchard et al. 10 A total of two additional cases (comparison group) were identified using this search parameter. Thus, it appears the predominant "indolent" MCL patient population seen at our center are those with a mild leukemic presentation lacking splenomegaly and gastrointestinal involvement as compared to indolent MCL patients previously described, 9 This may reflect the consolidated nature and integrated (bone marrow, blood and tissue) use of flow cytometry within the hematopathology service at our institutions. with SOX11 nuclear protein expression. 24 Consistent with other reports that state 78-93% of cases to be positive, we found the great majority (91%) of nodal MCL cases to express SOX11; however, in our cohort of indolent leukemic MCL cases only 1 of 5 showed low-level positivity. 9, 11, 21, 25 This was statistically different from typical nodal MCL. Interestingly, gene expression analysis identified a set of genes that may be useful in identifying indolent MCL cases. In particular, SOX11 may be an important biomarker, as SOX11 negative tumors tended to be non-nodal with better survival 9 . Our findings are more in keeping with the study by Fernandez et al, who showed a favorable outcome in SOX11 negative cases. 9 These data further support SOX11 as a potential prognostic biomarker in MCL assessable by IHC. While we can not fully reconcile our data with the putative tumor suppressor role for SOX11, one may speculate that in experimental systems and cell lines non-physiologic high levels of SOX11 expression might act in an anti-proliferative fashion. However, at more physiologic levels in mature cells, SOX11 is not a primary driver of a malignant phenotype and low/lack of expression as a favorable marker might be an epiphenomenon, albeit a useful one in recognizing the favorable phenotype.
Patterns of bone marrow involvement in stage IV conventional MCL are quite variable but are usually apparent on routine histopathology with H&E staining. Nonparatrabecular aggregates are seen more commonly than diffuse or paratrabecular infiltrates. 15,17,26, Bone marrow involvement in cases categorized as indolent-behavior mantle cell lymphoma is reportedly common(76-92%.) 7, 9 The pattern has not been well characterized but appears to have no prognostic relevance. 24 Bone marrow findings have not been described in leukemic, non-nodal disease patients that are presented here. We show that there is uniformly low tumor burden in the marrow with sparsely distributed interstitial single cyclin D1+ lymphocytes or, uncommonly, subtle interstitial aggregates, representing less than 5% of cellularity. This low tumor burden is in keeping with the generally indolent nature of the disease course.
Lack of CD5 expression has been reported in a small subset of patients with an indolent course, all of which had associated tissue (nodal) involvement. 4,5, 10 We found CD5 expression in all cases, accompanied by CD19, CD20 (bright), FMC7 and CD79b.
CD38 expression has been shown to predict lymph node involvement by MCL in that it is less often positive in patients who lack lymphadenopathy 10 , and was negative in all of our patients with available data (n=3). While flow cytometry has been described in a prior series 10 , Ig light chain usage has not been described. As opposed to the typical lambda predominance seen in MCL, we found a striking kappa light chain predominance (7 of 8, with the 8 th case being surface Ig negative). While this appears to be a near uniform feature in these leukemic non-nodal, clinically indolent cases, we are uncertain as to the underlying biology that would select for kappa over lambda light In summary, we report an indolent leukemic variant of MCL that can be recognized based on the constellation of incidentally discovered lymphocytosis with MCL peripheral blood morphology, lack of lymphadenopathy and hepatosplenomegaly, low level (usually <5%) interstitial bone marrow involvement, kappa light chain restriction, lack of SOX11 expression, and simple karyotype. The outcome appears quite favorable within the limits of our current follow-up, and awareness of this variant will allow future characterization of such cases and avoid over-treatment of such patients.
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